01OverviewDefinition, clinical context and the essential points that orientate the chapter.
Inflammatory breast cancer is an aggressive clinicopathological presentation in which tumour obstructs dermal lymphatics, producing rapid diffuse breast erythema, oedema and peau d’orange. A mass may be absent or obscured by swelling. The redness is easily mistaken for mastitis, cellulitis, allergic reaction or granulomatous inflammation, and early imaging can also be difficult because oedema increases tissue density.
The decisive safety principle is response and tissue diagnosis. A short initial infection pathway may be reasonable when lactational or bacterial features are convincing, but absent collection, abnormal nodes, progressive skin change or failure to improve demands urgent breast referral. Imaging maps breast and nodal targets; core establishes invasive carcinoma and biomarkers; skin punch may show dermal lymphatic emboli but a negative superficial sample does not overrule a compelling clinical and breast-biopsy diagnosis. Treatment planning belongs to the specialist multidisciplinary team.
Key points
- Inflammatory breast cancer is a clinical pattern of rapid erythema, oedema and enlargement caused by dermal lymphatic tumour involvement, often without a discrete palpable mass.
- Mastitis is more likely during lactation with pain, fever and milk-stasis triggers, but age or breastfeeding status alone cannot exclude cancer.
- Features of concern include peau d’orange, diffuse skin thickening, rapid progression, nipple change, abnormal nodes, absent pus and failure to respond to appropriate antibiotics and drainage.
- NICE NG12 says skin changes suggesting breast cancer should prompt consideration of a suspected-cancer pathway referral; do not require completion of multiple antibiotic courses first.
- Diagnostic work includes mammography and ultrasound of breast and nodes, core biopsy of breast abnormality and skin punch biopsy when needed to demonstrate dermal lymphatic invasion.
- Confirmed inflammatory cancer requires specialist neoadjuvant systemic therapy followed by local treatment planning; NICE NG101 recommends mastectomy, or exceptionally breast conservation, followed by radiotherapy after neoadjuvant chemotherapy.
02AetiologyUnderlying causes, associations and risk factors, with why each one matters.
Underlying invasive carcinoma
Inflammatory breast cancer is produced by biologically aggressive invasive carcinoma rather than by a separate inflammatory cell type.
Dermal lymphatic invasion
Tumour emboli enter superficial lymphatics and obstruct drainage, creating the characteristic diffuse skin and breast changes.
03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.
- 1Lymphatic obstruction
Tumour emboli block dermal lymphatic channels, causing interstitial fluid accumulation, skin thickening, oedema and tethering around hair follicles.
- 2Diffuse parenchymal spread
Tumour may infiltrate broadly without forming one dominant mass, making palpation and mammographic definition difficult initially.
- 3Early regional dissemination
Aggressive biology and lymphovascular invasion produce frequent nodal involvement and risk of distant spread at presentation.
04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.
Symptoms typically evolve over weeks with enlargement, warmth and erythema affecting a substantial breast area rather than one small focal cellulitic region.
Oedema around tethered hair follicles creates an orange-peel surface and may accompany heaviness, nipple retraction and loss of normal contour.
Axillary or supraclavicular nodes may be clinically or sonographically abnormal and provide an additional image-guided tissue target for staging.
Failure to show clear clinical improvement after an appropriate infection regimen and source-control assessment weakens bacterial mastitis and requires urgent tissue diagnosis.
05InvestigationsWhat to request, why it matters and how to interpret it.
Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.
- 01
Bilateral diagnostic mammographyFirst step - Why
- Identify mass, distortion, calcification, skin thickening and disease distribution.
- Interpretation and limitations
- Diffuse density and oedema may reduce sensitivity. A non-diagnostic study does not exclude inflammatory cancer and is complemented by ultrasound and biopsy.
- 02
Breast and axillary ultrasound - Why
- Locate a core-biopsy target, assess skin and find abnormal nodes or a true abscess.
- Interpretation and limitations
- Lack of a drainable cavity argues against abscess as the full explanation; suspicious parenchymal or nodal tissue should be sampled.
- 03
Image-guided core biopsy - Why
- Establish invasive malignancy, type, grade and receptor status from representative breast tissue.
- Interpretation and limitations
- Core is central to diagnosis and systemic treatment selection. Benign inflammation that fails to explain the phenotype is discordant and needs repeat targeting.
- 04
Skin punch biopsy - Why
- Demonstrate tumour emboli within dermal lymphatics when affected skin offers a diagnostic target.
- Interpretation and limitations
- Dermal involvement supports the diagnosis, but patchy emboli can be missed; interpret with clinical pattern and breast core rather than using a negative punch alone.
06Differential diagnosisRealistic alternatives and the features that help distinguish them.
Lactational or bacterial mastitis
Pain, fever, feeding trigger and response to antibiotics support infection, while persistence or absent collection demands biopsy.
Granulomatous mastitis
Sterile lobular inflammation can cause mass, sinuses and oedema and requires core tissue plus microbiological exclusion.
Congestive or dermatological oedema
Cardiac oedema, allergy and dermatitis can affect breast skin but should fit systemic distribution and lack malignant tissue targets.
07ManagementImmediate care, first-line treatment, alternatives and escalation.
01Non-resolving mastitis pathwayEscalate after failed appropriate treatmentFirst stepEscalationA non-lactating 58-year-old has diffuse erythema and swelling without an abscess and no improvement after a suitable antibiotic course.+
- 1Reassess the entire breast and nodes, documenting area of skin involvement, peau d’orange, nipple change, temperature and systemic state.
- 2Use the suspected-cancer route under NG12 rather than prescribing a second empirical course without a new infective finding.
- 3Arrange mammography, breast and axillary ultrasound, core biopsy of representative tissue and skin punch when clinically useful.
- 4Track pathology and receptor results to the breast multidisciplinary meeting and explain that lack of a discrete mass does not remove cancer concern.
02Parallel infection pathwayTreat pus without losing the cancer questionAn older patient has diffuse oedema plus a small ultrasound-confirmed collection and an abnormal axillary node.+
- 1Drain and culture the collection and treat sepsis appropriately because an infection can coexist with malignant lymphatic obstruction.
- 2Sample the abnormal node and residual breast tissue rather than assuming the entire diffuse phenotype is caused by the small cavity.
- 3Repeat skin and breast assessment as infection resolves, documenting any persistent peau d’orange and enlargement.
- 4Proceed with urgent cancer staging and treatment if pathology confirms malignancy while completing safe infection care.
03Confirmed-cancer pathwaySequence systemic and local treatmentCore confirms invasive HER2-positive carcinoma with an inflammatory clinical phenotype and involved axillary nodes.+
- 1Complete specialist staging and document ER, PR and HER2 because systemic regimen selection depends on biology and extent.
- 2Start neoadjuvant systemic treatment through oncology, monitoring skin extent, breast findings, nodes and treatment toxicity.
- 3After response, plan mastectomy, or exceptional breast-conserving treatment, and radiotherapy according to NICE NG101 and multidisciplinary assessment.
- 4Verify pathology, local treatment completion and a survivorship plan that addresses lymphoedema, recurrence signs and psychosocial recovery.
08ComplicationsImportant consequences, why they occur and why they matter clinically.
Rapid locoregional progression
Untreated dermal and parenchymal disease can extend across skin and chest wall and compromise local treatment options.
Distant metastasis
Aggressive biology and nodal involvement create substantial systemic relapse risk, necessitating staging and systemic therapy planning.
Diagnostic delay
Attribution to infection without response review can postpone biopsy through several antibiotic courses while disease progresses.
09Monitoring and follow-upTreatment response, safety checks and longer-term review.
- Photograph or map skin involvement with consent and record breast size, nipple contour and nodes so rapid progression and treatment response are measurable.
- When an infection trial is clinically justified, define an early response review rather than waiting through serial empirical courses.
- After neoadjuvant therapy, reassess clinical skin change, breast and nodal imaging and systemic toxicity before local treatment planning.
- Follow treated patients for new chest-wall erythema, nodules, swelling, nodes and distant symptoms under the oncology plan.
10Special situationsVariants, exceptions and circumstances that change the usual approach.
A mass is not required
Dermal lymphatic obstruction can dominate the presentation while the invasive primary is diffuse or difficult to palpate, so lump-focused examination alone is unsafe.
Punch biopsy can miss disease
Tumour emboli are patchy. A negative skin sample does not invalidate malignant breast core and a compelling inflammatory clinical pattern.
Small abscess may be incidental
A limited collection cannot explain whole-breast peau d’orange and abnormal nodes. Drain infection while sampling the remaining suspicious tissue.
Response does not erase biology
Improved redness after systemic treatment supports response but surgery and radiotherapy planning still follow initial inflammatory stage and multidisciplinary guidance.
11Common pitfallsFrequent interpretation and management errors.
- 01
Demanding a palpable mass before suspecting inflammatory cancer ignores its diffuse lymphatic presentation.
- 02
Repeating antibiotics after a non-responsive course without imaging or biopsy creates avoidable diagnostic delay.
- 03
Using a negative skin punch alone to exclude disease ignores patchy dermal emboli and the role of breast core histology.
- 04
Treating confirmed inflammatory cancer with surgery first bypasses the recommended neoadjuvant systemic sequence.